Crism Therapeutics Corporation
CRTX · AIM · Health Care · mcap £7.4m · 9.0p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 02 Oct 26 | Routine | Notice of AGM | |
| 21 Sep 26 | Results | Half-year Results
(“CRISM”, “CRISM Therapeutics”, the “Company” or the “Group”) |
+0.0% |
| 17 Sep 26 | Board change | Appointment of Non-executive Chair
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, is pleased to announce the appointment of Dr Charles Spicer as |
−9.3% |
| 20 Aug 26 | Commencement of Patient Recruitment
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. |
+0.0% | |
| 13 Aug 26 | Clinical Trial Update
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. |
+7.5% | |
| 29 Jul 26 | Holding | Holding(s) in Company | |
| 27 Jul 26 | Result of Shareholder Analysis
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that following the completion of an independent third |
+0.0% | |
| 02 Jul 26 | Holding | Holding(s) in Company | |
| 30 Jun 26 | Routine | Grant of Options | |
| 26 Jun 26 | Results | Final Results
'Regulatory milestones achieved and well-funded to advance Phase 2 Clinical Trial' |
+0.0% |
| 25 Jun 26 | Phase 2 Clinical Trial Progress Update
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. |
−2.4% | |
| 22 Jun 26 | Holding | Holding(s) in Company | |
| 16 Jun 26 | Holding | Holding(s) in Company | |
| 15 Jun 26 | Routine | Result of General Meeting | |
| 04 Jun 26 | Significant Grant Award
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. |
+4.5% | |
| 01 Jun 26 | Grant Award
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. |
+2.3% | |
| 28 May 26 | Fundraise | Result of Retail Offer
This Announcement does not constitute a prospectus or offering memorandum or an offer in respect of any securities and is not intended to provide the basis for any investment decision in respect of CRISM Therapeutics Cor |
+0.0% |
| 27 May 26 | Routine | Notice of General Meeting | |
| 26 May 26 | Fundraise | Retail Offer to raise up to £100,000
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, is pleased to announce a retail offer via BookBuild (the "Retai |
−8.7% |
| 26 May 26 | Fundraise | Placing of £2.5 million
This Announcement does not constitute a prospectus or offering memorandum or an offer in respect of any securities and is not intended to provide the basis for any investment decision in respect of CRISM Therapeutics Cor |
−8.7% |
| 21 Apr 26 | Positive Preclinical Data for Docetaxel ChemoSeed
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. |
+10.6% | |
| 02 Apr 26 | Board change | Directorate Change
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. |
−6.4% |
| 25 Mar 26 | Phase 2 Clinical Trial Progress Update
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. |
−11.8% | |
| 17 Mar 26 | Awarding of Orphan Drug Designation by the FDA
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. |
+20.8% | |
| 20 Jan 26 | Japanese Patent Grant
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that it has been granted a patent (7800909) by the Ja |
+2.5% | |
| 09 Jan 26 | Results | Results of Shareholder Analysis
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that following the completion of an independent third |
+0.0% |
| 15 Dec 25 | Fundraise | Result of Retail Offer
596/2014, AS INCORPORATED INTO UK LAW BY THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). |
+0.0% |
| 10 Dec 25 | Fundraise | Retail Offer
CRISM Therapeutics Corporation (the "Company") is pleased to announce a retail offer via BookBuild (the "Retail Offer") of new ordinary shares ("Ordinary Shares") of nil par value each in the capital of the Company (the |
−20.5% |
| 10 Dec 25 | Fundraise | Placing of £1,000,000
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. |
−20.5% |
| 27 Nov 25 | Holding | Holding(s) in Company | |
| 30 Oct 25 | US Orphan Drug Designation Application
Submission of Orphan Drug Designation Application to the FDA for Irinotecan-ChemoSeed™ in Glioblastoma |
+0.0% | |
| 14 Oct 25 | Positive Preclinical Data in Prostate Cancer
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. |
+0.0% |
Company filings. Not investment advice.